A SILENT CRISIS: Tuberculosis Drug Shortages in the United States

On January 18, 2013, in Washington, D.C., TAG held a consultation on the domestic TB drug shortage crisis. The meeting was cosponsored by PATH, RESULTS, the Center for Global Health Policy, and the American Thoracic Society.

Welcome and Agenda Overview

Introductory Comments and FDA Perspective on Drug Shortages
Captain Jouhayna Saliba, Pharm.D – CDER Drug Shortage Program, Food and Drug Administration

Ann M. Cronin, Associate Director for Policy and Issues Management, Division of TB Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention

Overview of TB Drug Shortages in the U.S. – Causes and Significant Trends
Dr. Sundari Mase – Team Lead for Medical Affairs, Field Services and Evaluation Branch, CDC Division of Tuberculosis Elimination

TB Patient Perspective
Liliana Torres – MDR-TB Survivor
Dr. Barbara Seaworth – Medical Director, Heartland National TB Center

Public Health Impact of Drug Shortages – Case Study from Baltimore City
Dr. Maunank Shah – Medical Director, Baltimore City Health Department TB Program

Impact of First-Line Drug Shortages on Domestic TB Control and Prevention Programs
Dr. Jon Warkentin – President, National Tuberculosis Controllers Association and Tennessee State TB Control Officer

The Global Drug Facility mechanism and new strategy to avoid in country TB drugs stock-outs
Dr. Joël Keravec – Global Drug Facility Manager a.i., Stop TB Partnerships / WHO Geneva

State and Federal Advocacy
Global Advocacy

Summation